The OVAL Study: A Randomized, Controlled, Double-Arm,Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
J
Jeanne Schilder, MD
Primary Investigator
Not Recruiting
18 years - 100 years
Female
1 Location
Brief description of study
The purpose of this study is to compare the efficacy and safety of the experimental drug VB-111 in combination with the standard chemotherapy drug paclitaxel compared to using paclitaxel combined with placebo.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Ovarian Cancer
-
Age: 18 years - 100 years
-
Gender: Female
Inclusion Criteria
In order to be eligible to take part in this trial, patients must meet the following criteria:
- Histologically confirmed epithelial ovarian cancer and documented disease.
- Patients must have platinum-resistant disease.
For a full list of participation criteria, please visit clinicaltrials.gov.
Updated on
01 Aug 2024.
Study ID: 1901313859 (VB-111-701/GOG-3018)
